- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04663295
MiniMed™ 670G System China Study for Type I Diabetic
Safety, Effectiveness and Usability Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Adult and Adolescent Subjects in Chinese Population
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a multi-center, single arm study in insulin-requiring subjects with type 1 diabetes who are 14 years of age and older. The run-in period will be approximately up to 35 days long, followed by a study period that will be approximately up to 33 days in duration.
The study is anticipated to last no longer than 13 months from investigational center initiation to completion of all data entry and monitoring procedures. The study will target approximately 5 months to complete subject enrollment. Subjects can expect to participate for approximately 2-3 months including the run-in and study periods.
A total of up to 75 subjects (aged 14-75) will be enrolled at a minimum 2 investigational centers and up to 6 investigational centers (hospitals) in China to have at least 50 subjects who complete the study.
The MiniMed™ HCL system that was employed in this study was the MiniMed™ 670G Bluetooth version (MMT-1883). The MiniMed™ 670G system with Bluetooth™ technology is the MiniMed™ 770G system.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Chinese PLA General Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- The First Affiliated Hospital, Sun Yat-sen University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Shanghai General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is age 14- 75 years at time of Screening.
Subject has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
Study-specific inclusion criteria
- Subject is willing to perform ≥ 4 finger stick BG measurements daily.
- Subject is willing to perform required sensor calibrations.
- Subject is willing to wear the system continuously throughout the study.
- Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units.
- Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by the investigational center lab or their contracted Local Lab) at time of Screening visit.
- Subject has thyroid-stimulating hormone (TSH) in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range. Prior labs in the last 6 months are sufficient.
- Subject has been on pump therapy for greater than 6 months prior to screening (with or without CGM experience).
- Subject is willing to upload data from the study pump and meter at home.
- If subject has celiac disease, it has been adequately treated as determined by the investigator.
Subject has been taking and is willing to take one of the following insulins throughout the course of the study:
- Humalog™* (insulin lispro injection)
- NovoLog™* (insulin aspart)
- Subject must be able to carbohydrate count or willing to learn how to carbohydrate count for the study.
Exclusion Criteria:
Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to Screening:
- Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
- Coma
- Seizures
- Subject has been hospitalized or has visited the ER in the 6 months prior to Screening resulting in a primary diagnosis of uncontrolled diabetes.
- Subject has had DKA in the 6 months prior to Screening.
- Subject is unable to tolerate tape adhesive in the area of sensor placement.
- Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
- Subject is a female of child-bearing potential who has a positive pregnancy test at Screening or plans to become pregnant during the course of the study.
- Subject is a female who is sexually active and able to conceive should be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
- Subject has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease.
- Subject is being treated for hyperthyroidism at time of Screening.
- Subject has a diagnosis of adrenal insufficiency.
- Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of Screening, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.
- Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks. (Please note participation in an observational study is acceptable.)
- Subject is currently abusing illicit drugs.
- Subject is currently abusing alcohol.
- Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Screening.
- Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.
- Subject has elective surgery planned that requires general anesthesia during the course of the study.
- Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of Screening
- Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation.
- Subject diagnosed with current eating disorder such as anorexia or bulimia
- Subject has been diagnosed with chronic kidney disease that results in chronic anemia.
- Subject has a hematocrit (Hct) that is below the normal reference range of lab used. Prior labs in the last 6 months are sufficient.
- Subject is on dialysis.
- Subject has an estimated glomerular filtration rate (eGFR) of < 30.
- Subject has a pediatric BMI category of underweight (less than the 5th percentile) as defined by Centers for Disease Control (CDC) (https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html)
- Subject is a member the research staff involved with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Subjects with Type 1 diabetes wearing HCL pump system
Subjects 14-75 years of age who have been diagnosed with Type 1 diabetes.
|
Hybrid closed loop insulin pump with associated CGM and blood glucose meter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L)
Time Frame: Baseline to end of 1-month study
|
The overall mean change in % of time in target range from run-in period to study period will be estimated and compared by a simple superiority paired test and a significance level of 0.025 (one-sided).
|
Baseline to end of 1-month study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in Hypoglycemic Range
Time Frame: 1-month study
|
Time in hypoglycemic range (% of SG): SG < 70 mg/dL (3.9 mmol/L), SG < 60 mg/dL (3.3 mmol/L), SG < 54 mg/dL (3.0 mmol/L) will be summarized.
|
1-month study
|
Time in Hyperglycemic Range: SG > 180 mg/dL (10 mmol/L), 250 mg/dL (13.9 mmol/L) and 350 mg/dL (19.4 mmol/L)
Time Frame: 1-month study
|
Time in hyperglycemic range (SG > 180 mg/dL (10 mmol/L), 250 mg/dL (13.9 mmol/L) and 350 mg/dL (19.4 mmol/L)) will be summarized.
|
1-month study
|
Standard Deviation (SD) of SG in mmol/L
Time Frame: 1-month study
|
In order to evaluate glucose variation, we calculated standard deviation.
The standard deviation (SD) of SG will be summarized in the unit of mmol/L
|
1-month study
|
Standard Deviation (SD) of SG in mg/dL
Time Frame: 1-month study
|
In order to evaluate glucose variation, we calculated standard deviation.
The standard deviation (SD) of SG will be summarized in the unit of mg/dL.
|
1-month study
|
Coefficient of Variation (CV) of SG
Time Frame: 1-month study
|
In order to evaluate glucose variation, we calculated coefficient of variation (CV) of SG.
The glucose coefficient of variation (CV) will be summarized in percentage.
|
1-month study
|
Change of Total Daily Dose (TDD) of Insulin From Baseline to End of Study (EOS)
Time Frame: Baseline to end of 1-month study
|
Change of Total Daily Dose (TDD) of insulin from baseline to EOS will be summarized.
|
Baseline to end of 1-month study
|
Change of Weight From Baseline to EOS
Time Frame: Baseline to end of 1-month study
|
Change of weight from baseline to EOS will be summarized.
|
Baseline to end of 1-month study
|
Time Spent in Auto Mode (HCL) Versus Time Spent in Manual Mode (Open Loop)
Time Frame: 1-month study
|
Time spent in Auto Mode (HCL) and time spent in Manual Mode (open loop) will be summarized.
|
1-month study
|
Time in Specific Range Stratified by Baseline HbA1c Ranges (< 7%, 7 - < 7.5%, 7.5 - 8%, > 8%)
Time Frame: 1-month study
|
Time in target range (% of SG): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L) in study period Time in hypoglycemic range (% of SG): SG < 70 mg/dL (3.9 mmol/L), 60 mg/dL (3.3 mmol/L) and 54 mg/dL (3.0 mmol/L) in study period Time in hyperglycemic range: SG > 180 mg/dL (10 mmol/L), 250 mg/dL (13.9 mmol/L) and 350 mg/dL (19.4 mmol/L) in study period
|
1-month study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yiming Mu, MD, Chinese PLA General Hospital
- Principal Investigator: Yan Bi, MD, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Principal Investigator: Yongde Peng, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Principal Investigator: Yanbing Li, MD, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP329
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on MiniMed™ 670G system
-
Rabin Medical CenterMedtronic; GIFCompleted
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingHypoglycemia | Type1diabetes | Nocturnal Hypoglycemia | Hypoglycemia Unawareness | Hypoglycemia NightUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingDiabetes Mellitus, Type 1Belgium
-
Medtronic DiabetesCompleted
-
Medtronic DiabetesCompletedType 1 DiabetesNetherlands, France, Italy, United Kingdom
-
Kinderkrankenhaus auf der BultCompletedDrug Therapy | Patient CareGermany
-
HealthPartners InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Yale... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States, Germany, Slovenia, Israel
-
Hamad Medical CorporationSidra MedicineUnknown
-
Sidra Medical and Research CenterCompletedDiabetes Mellitus, Type 1Qatar
-
University of Ljubljana, Faculty of MedicineCompletedType 1 Diabetes MellitusSlovenia, Israel